Isa Pharmaceuticals

isa pharmaceuticals b.v. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. the company has built a proprietary immunotherapy platform based on the synthetic long peptide (slp®) concept and amplivant® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as nivolumab. slp® immunotherapies are designed to fully harness and direct the body‘s own defenses towards fighting the disease. in addition, isa has begun to develop personalized slp® immunotherapies targeting tumor specific, mutation derived neo-antigens. these slp®’s are based on the analysis of the specific dna mutations in a tumor sample and designed and synt